Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Update

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the recipient of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 3,400,000 shares, a drop of 13.7% from the February 28th total of 3,940,000 shares. Approximately 6.2% of the shares of the stock are sold short. Based on an average daily volume of 781,700 shares, the days-to-cover ratio is currently 4.3 days.

Wall Street Analyst Weigh In

AGIO has been the topic of several research analyst reports. StockNews.com downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Royal Bank of Canada raised their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a report on Tuesday, December 10th. Scotiabank increased their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, December 9th. Finally, HC Wainwright began coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $56.57.

Remove Ads

Agios Pharmaceuticals Trading Down 7.0 %

Shares of NASDAQ AGIO traded down $1.95 during midday trading on Friday, reaching $25.76. 1,192,473 shares of the company were exchanged, compared to its average volume of 709,084. The stock has a market cap of $1.48 billion, a P/E ratio of 2.27 and a beta of 0.83. Agios Pharmaceuticals has a 1 year low of $25.26 and a 1 year high of $62.58. The stock has a fifty day simple moving average of $32.55 and a 200 day simple moving average of $40.19.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, analysts forecast that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.

Insider Activity at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the company's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now owns 18,906 shares of the company's stock, valued at $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.93% of the company's stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. State Street Corp raised its position in Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock worth $103,586,000 after acquiring an additional 216,484 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Agios Pharmaceuticals by 15.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock valued at $531,000 after purchasing an additional 1,570 shares in the last quarter. FMR LLC lifted its stake in shares of Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock valued at $2,017,000 after purchasing an additional 33,546 shares during the period. Venturi Wealth Management LLC purchased a new stake in Agios Pharmaceuticals during the fourth quarter worth about $33,000. Finally, Franklin Resources Inc. acquired a new position in Agios Pharmaceuticals during the third quarter worth about $1,499,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.